The influence of serotonin transporter polymorphisms on cortical activity: A resting EEG study by Lee, Tien-Wen et al.
RESEARCH ARTICLE Open Access
The influence of serotonin transporter
polymorphisms on cortical activity: A resting EEG
study
Tien-Wen Lee
1,2, Younger WY Yu
3, Chen-Jee Hong
4,5, Shih-Jen Tsai
4,5, Hung-Chi Wu
6 and Tai-Jui Chen
7,8*
Abstract
Background: The serotonin transporter gene (5-HTT) is a key regulator of serotonergic neurotransmission and has
been linked to various psychiatric disorders. Among the genetic variants, polymorphisms in the 5-HTT gene-linked
polymorphic region (5-HTTLPR) and variable-number-of-tandem-repeat in the second intron (5-HTTVNTR) have
functional consequences. However, their genetic impact on cortical oscillation remains unclear. This study
examined the modulatory effects of 5-HTTLPR (L-allele carriers vs. non-carriers) and 5-HTTVNTR (10-repeat allele
carriers vs. non-carriers) polymorphism on regional neural activity in a young female population.
Methods: Blood samples and resting state eyes-closed electroencephalography (EEG) signals were collected from
195 healthy women and stratified into 2 sets of comparisons of 2 groups each: L-allele carriers (N = 91) vs. non-
carriers for 5-HTTLPR and 10-repeat allele carriers (N = 25) vs. non-carriers for 5-HTTVNTR. The mean power of 18
electrodes across theta, alpha, beta, gamma, gamma1, and gamma2 frequencies was analyzed. Between-group
statistics were performed by an independent t-test, and global trends of regional power were quantified by non-
parametric analyses.
Results: Among 5-HTTVNTR genotypes, 10-repeat allele carriers showed significantly low regional power at gamma
frequencies across the brain. We noticed a consistent global trend that carriers with low transcription efficiency of
5-HTT possessed low regional powers, regardless of frequency bands. The non-parametric analyses confirmed this
observation, with P values of 3.071 × 10
-8 and 1.459 × 10
-12 for 5-HTTLPR and 5-HTTVNTR, respectively.
Conclusions and Limitations: Our analyses showed that genotypes with low 5-HTT activity are associated with
less local neural synchronization during relaxation. The implication with respect to genetic vulnerability of 5-HTT
across a broad range of psychiatric disorders is discussed. Given the low frequency of 10-repeat allele of 5-HTTVNTR
in our research sample, the possibility of false positive findings should also be considered.
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Background
Serotonin or 5-hydroxytryptamine (5-HT) is a monoa-
mine derived from tryptophan and is abundant in the
gastrointestinal tract, platelets, and the central nervous
system. Serotonin acts as a neurotransmitter in the
brain. 5-HT transporter (5-HTT) plays a central role in
regulating 5-HT synaptic function by transporting the
neurotransmitter serotonin from synaptic spaces into
pre-synaptic neurons. Among the genetic variants of 5-
HTT, polymorphisms in the 5-HTT gene-linked poly-
morphic region (5-HTTLPR)a n dv a r i a b l e - n u m b e r - o f -
tandem-repeat in the second intron (5-HTTVNTR)h a v e
functional consequences and are of particular interest.
Although it is still debatable [1], the functional poly-
morphisms of the 5-HTT gene have been reported to
influence susceptibility to traumatic experience and risk
for various forms of depression, anxiety, psychosis, alco-
holism, and suicidal behaviors [2-12]. Further, low
expression of 5-HTT is associated with increased
adverse effects and reduced treatment response to anti-
depressants [13-15].
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polymorphism (S: S-allele, L(A/G): L-allele) have been
under active study. The L-/S-allele reflect a 43-bp inser-
tion/deletion in the 5-HTT-linked polymorphic region,
wherein the long variant is more than twice as active as
the short variant [16]. A single nucleotide polymorphism
of A/G (rs25531) within the L-allele was reported to
lead to two functionally different variants, with the tran-
scriptional activity of the less common G substitution
similar to that of the S-allele [17]. Risk allele carriers (S
or L(G)) with low expression of 5-HTT showed
increased amygdala reactivity to masked emotional faces
and to overtly sad faces [18,19]. In the resting state, the
subjects carrying homozygous S-alleles showed increased
and decreased cerebral blood flow in the amygdala and
in the ventromedial prefrontal cortex, respectively [20].
Enhanced basal metabolism in fronto-limbic structures
for carriers homozygous for S-alleles was regarded to
enhance the susceptibility for developing an anxiety-
depression spectrum disorder [21].
Compared with 5-HTTLPR, the neural mechanism influ-
enced by 5-HTTVNTR polymorphism (e.g., 10-repeat and
12-repeat) is much less clear, with the 10-repeate allele
bearing lower transcription efficiency than the 12-repeat
one. Similar to the imaging studies of 5-HTTLPR,B e r t o -
lino et al. noticed that the 5-HTTVNTR genotype pre-
dicted amygdala activity to threatening stimuli [22].
However, the findings of 5-HTTVNTR and 5-HTTLPR
seemed not always convergent. For example, the studies
on 5-HTTLPR and 5-HTTVNTR have shown that 5-
HTTLPR genotypes did not differentiate the degree of
harm avoidance but 5-HTTVNTR did [23]. Preferential
transmission of 5-HTTLPR not 5-HTTVNTR genotypes
has been reported for autism [24,25]. A tendency toward
an increase in the 5-HTTLPR L-allele and VNTR 10-
repeat allele, not 12-repeat, has been observed in suicide
victims [26]. The inconsistency raised a concern that the
consequence of 5-HTTLPR and 5-HTTVNTR genotypes
(although both affect the transcription efficiency of 5-
HTT) cannot be fully explained by differential serotonin
levels at the neural cleft. Thus, whether the neuroimaging
findings based on 5-HTTLPR can be extrapolated to 5-
HTTVNTR warrants empirical examination.
The serotonin system exerts a complicated impact on
the neuromatrix of electrocortical activities. Since the
function of 5-HTT is related to the clearance of seroto-
nin in the neural cleft, it is pertinent to refer to the
pharmaco-EEG studies contingent on enhanced (e.g.
administration of serotonin reuptake inhibitors) or
reduced (e.g. acute tryptophan depletion) serotonergic
neurotransmission. Acute enhancement of serotonin
level produces a widespread decrease in slow and med-
ium frequency activity and an increase in fast frequency
activity on electroencephalography (EEG) scans;
however, a reduced serotonin level is also associated
with decreased delta/theta and increased alpha/beta
powers [27,28]. Knott et al. observed that the reduction
in central serotonin caused a significant and widespread
increase in slow wave delta amplitude [29]. Administra-
tion of serotonin reuptake inhibitors is related to
reduced slow wave and increased alpha or beta activities
[30,31] but negative EEG alteration has also been
reported [32]. In summary, the extant literature seems
inconclusive with respect to the interaction between ser-
otonergic neurotransmission and electrocortical oscilla-
tion. The effects of global serotonin level on event-
related potentials are more consistent but showed con-
textual dependency. For example, acute tryptophan
depletion is associated with suppressed P50/N1
enhancement to target, decreased intensity dependence
of N1m/P2m in auditory cortex, reduced N2 amplitude
in mismatch negativity and attenuated N1P2/P300
amplitudes in oddball design (for patients of bipolar dis-
orders; without EEG power change) [33-36], while nega-
tive findings are noticed in somatosensory stimulation
and episodic memory retrieval [37,38]. Nevertheless, it
was also reported that no significant alterations in audi-
tory evoked potentials and background EEG power/fre-
quency followed acute tryptophan depletion [39].
Thus far, only a few studies have investigated the
change in quantitative EEG (qEEG) indices stratified by
5-HTTLPR and 5-HTTVNTR genetic polymorphisms.
The risk allele of 5-HTTLPR is related to mildly
increased right frontal asymmetry and imposes no direct
effect on target N1 and novelty N1 potentials [40,41].
The more active variant of serotonin transporter is asso-
ciated with enhanced mismatch negativity and decreased
P300 components [42]. Whether the differential expres-
sion of the serotonin transporter alters neural character-
istics in the resting state remains unexplored. This study
used EEG to investigate the effect of 5-HTTLPR and 5-
HTTVNTR on local brain dynamics in the resting state.
Resting EEG carries abundant information predictive of
performance on several neuro-psychological tasks and
even the early stage of Alzheimer’s disease or the treat-
ment response in major depressive disorders [43-48].
O u rd e s i g na l s oe x a m i n e da ni s s u eo fw h e t h e rt h e
neural manifestation of 5-HTTLPR and 5-HTTVNTR
polymorphisms would converge. Since the gender differ-
ence has been noticed to moderate the association
between the polymorphism of the serotonin transporter
and various phenotypes [49-51], we restricted this
research sample to women.
Materials and methods
Subjects
In this study, 208 right-handed healthy young women of
a nursing college were enrolled. Their ages ranged from
Lee et al. BMC Neuroscience 2011, 12:33
http://www.biomedcentral.com/1471-2202/12/33
Page 2 of 1019 to 21 years. Neurological and physical examinations
were performed by licensed medical doctors, while their
psychiatric condition was evaluated by licensed psychia-
trists following a semi-structural interview process.
Those with a history of substance abuse, psychiatric dis-
ease, or major medical or neurological disorders were
excluded. Only those who had been medication-free,
including birth control pills, for at least 2 weeks were
enrolled. This project was approved by the institutional
ethics committee, conforming with The Code of Ethics
of the World Medical Association. Informed consent
was obtained from all participants before beginning the
investigation. Based on the exclusion criteria, 13 partici-
pants were not eligible and 195 participants were
included in the analysis.
EEG recordings and analyses
All participants underwent a 3-minute conventional, eyes-
closed, awake, digital EEG scan after a 5-minute habitua-
tion to the experimental environment (Brain Atlas III
computer, Biologic System Company, Chicago). Record-
ings followed the standard of the international 10-20 sys-
tem with ear-linked reference at a 256 Hz sampling rate
and impedance below 3 kΩ [52]. The artifact of vertical
eyeball movement was detected from electrodes placed
above and below the right eye, with the horizontal analog
derived from electrodes placed at the left outer canthus.
The frequency bands were defined as follows: theta, 4-8
Hz; alpha, 8-12 Hz; beta, 12-24 Hz; gamma, 25-60 Hz;
gamma1, 25-35 Hz; and gamma2, 35-60 Hz. EEG traces
with artifacts were deleted by experienced EEG research-
ers. Eighteen electrodes, namely, F7, F3, Fz, F4, F8, T3, C3,
C z ,C 4 ,T 4 ,T 5 ,P 3 ,P z ,P 4 ,T 6 ,O 1 ,O z ,a n dO 2w e r e
included in the analyses. We used Fast Fourier Transform
to derive the mean EEG power (unit: μV
2).
Genotyping of 5-HTTLPR and 5-HTTVNTR polymorphisms
G e n o m i cD N Aw a si s o l a t e df r o mp e r i p h e r a ll e u k o c y t e s
and amplified using polymerase chain reaction, with the
primers 5-HTTLPR-3: ATGCCAGCACCTAACCCC-
TAATG plus 5-HTTLPR-2: GAGGGACTGAGCTGGA-
CAACCAC [16], and 5-HTTVNTR-F: GTCAGTAT
CACAGGCTGCGAG plus 5-HTTVNTR-B: TGTTCC
TAGTCTTACGCCAGTG [8]. Polymorphisms of 5-
HTTLPR and 5-HTTVNTR were identified using agar-
ose-gel electrophoresis. The sizes of the S- and L-alleles
for 5-HTTLPR were 469-470 bp and 511-513 bp, respec-
tively, and the sizes of the 10-repeat and 12-repeat
alleles for 5-HTTVNTR were 267 bp and 300 bp,
respectively.
Statistical analyses
Pair-wise linkage disequilibrium and Hardy-Weinberg
equilibrium were analyzed using ARLEQUIN 2.000 [53].
We performed 2 independent calculations of gene-brain
interaction, and the participants were categorized into 2
groups according to the genotypes of 5-HTTLPR and 5-
HTTVNTR.F o r5-HTTLPR, the stratification was based
on L-allele carriers (L/L and L/S) and non-carriers (S-
allele homozygotes). For 5-HTTVNTR, the subjects were
grouped into 10-repeat allele carriers (10/10 and 10/12)
and non-carriers (12-repeat allele homozygotes). An
independent 2-sample t-test that assumed unequal var-
iance was performed to elucidate the channel-frequency
pairs with values of mean power showing significant
between-group differences. Two-way ANOVA was car-
ried out to investigate the interaction between the geno-
types of 5-HTTLPR and 5-HTTVNTR on the cortico-
electrical power. For each test set in this study, the cri-
terion for significance was set at P < 0.05, two-tailed.
We assumed the independency of each frequency band
and performed a Bonferroni correction based on the for-
mula P = 1 - (1 - 0.05)
1/n, where n equals the number of
comparisons. For each comparison, we reported both
the P value < 0.01 and the P value adjusted for multiple
comparisons (0.0028 when n = 18), in case the Bonfer-
roni correction is too stringent since the cortical electri-
cal activities are interactive, not totally independent.
To test whether there was a global trend difference in
the mean power across regions and frequency bands
between genotyped groups, we performed non-parametric
analyses. Our null hypothesis assumed that the probability
of a certain index (i.e., mean power) for a particular elec-
trode at a specific frequency band, group one is greater
than group two equals the probability that group two is
greater than group one (i.e., the probability was 0.5). The
probability to obtain j or more “group one > group two”
indices by chance can be calculated using the following
formula: P =
s 
k=j
(s
k) × 0.5s, where s is the total number of
comparisons (one comparison for each electrode-fre-
quency couple, e.g., F3-alpha; s = 18 × 6 when taking all
the electrode(18)-frequency(6) pairs into account).
Power analysis was conducted according to 2 funda-
mental perspectives [54]: (1) Estimate the sample num-
ber required to reach fixed type I and type II errors in
the independent 2-sample t-test. (2) Estimate the z-
score of power under fixed type I error and sample sta-
tistics (mean, variance and sample number). We per-
formed power analyses for each electrode-frequency pair
for 5-HTTLPR and 5-HTTVNTR. Interested readers may
refer to the cited reference for mathematical details [54].
Results
The 5-HTTLPR genotypes of the participants included
L/L (N = 16), S/L (N=75), and S/S (N =1 0 4 ) ,a n d
these were distributed in Hardy-Weinberg equilibrium
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2 = 0.226, P = 0.634). The subjects were divided into 2
groups: 104 S-allele homozygotes and 91 L-carriers (S/L
and L/L). The 5-HTTVNTR genotypes of the partici-
pants included 12/12 (N = 170), 12/10 (N=24), and
10/10 (N = 1) and were also distributed in Hardy-Wein-
berg equilibrium (c
2 =0 . 0 2 4 ,P = 0.878). The subjects
were divided into 2 groups: 170 12-repeat allele homo-
zygotes and 25 10-repeate allele carriers (12/10 and 10/
10). The haplotype analysis detected no significant link-
age disequilibrium between the 5-HTTLPR and 5-
HTTVNTR polymorphisms (p = 0.237), which repli-
cated previous observation [55].
As to the between-group comparisons for 5-HTTLPR
and 5-HTTVNTR, the values and statistics of mean
power over 18 channel pairs across 6 frequency bands
are summarized in Tables 1 and 2, respectively. For the
Table 1 Comparison of regional mean power in 5HTTLPR L-allele carriers (upper row) and non-carriers (S allele
homozygotes; lower row) for each EEG channel
theta alpha beta gamma gamma1 gamma2
F7 12.26 (11.27) 21.56 (20.07) 3.19 (3.83) 1.12 (2.35) 1.54 (2.93) 0.95 (2.14)
10.74 (8.29) 19.49 (18.55) 3.01 (2.26) 0.85 (1.03) 1.21 (1.19) 0.70 (0.98)
F3 19.63 (16.35) 37.84 (34.03) 4.55 (4.73) 0.93 (1.33) 1.61 (2.35) 0.66 (0.98)
17.07 (13.07) 36.61 (38.50) 4.52 (3.66) 0.84 (0.87) 1.43 (1.23) 0.61 (0.77)
Fz 27.91 (22.14) 52.89 (46.77) 5.48 (5.43) 0.97 (1.22) 1.58 (2.28) 0.73 (0.96)
24.65 (18.95) 51.37 (52.85) 5.66 (5.06) 0.93 (0.85) 1.40 (1.15) 0.74 (0.90)
F4 23.23 (18.72) 43.37 (37.89) 5.17 (5.02) 1.11 (1.63) 1.90 (2.74) 0.80 (1.28)
20.10 (15.43) 43.28 (46.09) 5.35 (4.49) 1.02 (1.05) 1.72 (1.52) 0.74 (0.92)
F8 12.43 (9.98) 20.93 (17.84) 3.10 (2.84) 1.01 (1.82) 1.45 (2.38) 0.84 (1.61)
10.63 (7.90) 21.54 (23.04) 3.03 (2.28) 0.83 (1.07) 1.18 (1.15) 0.69 (1.05)
T3 13.95 (12.03) 26.45 (28.25) 4.79 (5.09) 1.77 (2.94) 2.34 (3.73) 1.54 (2.69)
11.61 (8.74) 24.59 (20.44) 4.26 (3.44) 1.10 (1.13) 1.55 (1.39) 0.92 (1.05)
C3 27.28 (21.80) 52.91 (51.58) 6.26 (5.59) 1.12 (1.43) 1.88 (2.30) 0.82 (1.16)
23.47 (17.52) 49.63 (45.78) 6.47 (5.25) 0.96 (0.90) 1.66 (1.33) 0.68 (0.79)
Cz 33.54 (26.92) 63.34 (58.95) 6.33 (6.12) 0.95 (1.26) 1.70 (2.23) 0.65 (0.97)
29.01 (21.98) 60.67 (61.58) 6.36 (5.38) 0.82 (0.71) 1.62 (1.62) 0.50 (0.42)
C4 28.69 (23.64) 57.32 (53.89) 6.53 (5.85) 1.07 (1.32) 1.86 (2.25) 0.75 (1.02)
24.19 (18.01) 53.81 (50.71) 6.50 (5.15) 0.92 (0.88) 1.64 (1.31) 0.63 (0.75)
T4 14.91 (12.54) 27.17 (24.27) 5.42 (6.34) 1.99 (3.67) 2.58 (4.14) 1.75 (3.50)
13.00 (9.96) 28.14 (25.30) 4.71 (3.76) 1.33 (1.88) 1.87 (2.21) 1.12 (1.76)
T5 17.00 (15.02) 48.72 (54.64) 5.20 (4.91) 1.15 (2.13) 1.67 (2.75) 0.94 (1.94)
15.82 (19.68) 62.30 (100.16) 6.87 (14.47) 0.88 (1.08) 1.40 (1.52) 0.67 (0.93)
P3 26.87 (23.61) 68.13 (73.30) 7.05 (6.07) 0.85 (0.97) 1.53 (1.69) 0.58 (0.71)
23.16 (19.05) 68.06 (65.39) 7.96 (9.69) 0.78 (0.69) 1.46 (1.20) 0.51 (0.51)
Pz 32.34 (26.84) 77.32 (77.78) 7.36 (6.55) 0.88 (0.98) 1.58 (1.67) 0.60 (0.76)
27.80 (22.29) 78.06 (76.74) 7.66 (8.45) 0.76 (0.58) 1.45 (1.05) 0.49 (0.41)
P4 26.28 (21.78) 71.78 (71.84) 7.30 (5.94) 0.86 (0.93) 1.54 (1.51) 0.59 (0.73)
23.45 (18.50) 78.70 (84.64) 8.49 (12.28) 0.76 (0.59) 1.44 (1.05) 0.49 (0.44)
T6 19.07 (16.11) 82.44 (96.34) 6.93 (6.88) 1.32 (3.07) 2.02 (4.26) 1.05 (2.62)
17.75 (16.44) 89.91 (105.76) 8.46 (17.75) 0.92 (0.87) 1.55 (1.42) 0.67 (0.69)
O1 26.89 (24.71) 129.21 (140.92) 9.33 (8.05) 1.19 (1.61) 1.91 (2.24) 0.90 (1.40)
23.93 (26.70) 149.02 (232.99) 13.68 (33.71) 1.18 (1.90) 2.03 (2.93) 0.84 (1.55)
Oz 26.38 (21.76) 148.51 (149.64) 10.17 (8.30) 1.16 (1.62) 1.89 (1.94) 0.86 (1.55)
23.59 (25.14) 159.84 (239.83) 13.67 (32.34) 0.98 (0.94) 1.77 (1.82) 0.66 (0.66)
O2 32.23 (26.29) 118.62 (121.38) 12.03 (10.49) 1.94 (2.32) 3.19 (3.71) 1.44 (1.81)
29.96 (24.62) 128.54 (148.79) 14.84 (25.75) 2.11 (3.09) 3.50 (4.85) 1.56 (2.43)
The mean power (×100) was expressed as “mean (STD)”
None of the between-group differences reached statistical significance (P < 0.01)
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allele carriers vs. non-carriers), none of the electrode-
frequency pairs reached statistical significance. However,
for 5-HTTVNTR genotypes (10-repeat allele carriers vs.
non-carriers), the electrode-frequency pairs showing sig-
nificant genotype effect aggregated at gamma frequen-
cies and were widely distributed across the brain. Since
EEG gamma power is susceptible to muscular artifacts,
we plotted the topography of t-statistics for between-
group comparisons for 5-HTTVNTR (Figure 1). The
strongest peaks were away from the bi-temporal region,
indicating that the significant results did not likely origi-
nate from electromyographical activities of the musculus
temporalis, masseter muscle, etc.
Table 2 Comparison of regional mean power of 5HTTVNTR 10-repeat allele carriers (lower row) and non-carriers (12-
repeat allele homozygotes; upper row) for each EEG channel
theta alpha beta gamma gamma1 gamma2
F7 12.34 (11.39) 21.47 (19.46) 3.31 (3.33) 1.03 (1.80)* 1.45 (2.22) 0.86 (1.65)*
11.33 (7.85) 18.75 (14.42) 2.54 (1.34) 0.54 (0.41) 0.86 (0.54) 0.41 (0.37)
F3 19.60 (17.62) 38.50 (36.18) 4.81 (4.53) 0.94 (1.11)* 1.62 (1.87)* 0.67 (0.88)*
16.86 (12.45) 31.66 (25.56) 3.54 (2.12) 0.52 (0.37) 0.95 (0.61) 0.35 (0.30)
Fz 28.09 (23.74) 53.91 (49.44) 5.90 (5.47) 1.00 (1.05) 1.58 (1.79) 0.76 (0.96)
24.97 (19.24) 46.74 (37.98) 4.63 (3.10) 0.61 (0.55) 0.98 (0.71) 0.46 (0.60)
F4 23.04 (18.98) 44.94 (41.90) 5.56 (4.93) 1.13 (1.36)* 1.91 (2.24)* 0.82 (1.11)*
20.68 (16.11) 37.52 (30.52) 4.30 (2.58) 0.63 (0.44) 1.16 (0.74) 0.42 (0.37)
F8 12.38 (10.52) 21.94 (20.52) 3.24 (2.75) 0.93 (1.45) 1.35 (1.83) 0.77 (1.32)
12.01 (9.66) 19.45 (15.16) 2.63 (1.49) 0.60 (0.61) 0.93 (0.75) 0.46 (0.57)
T3 14.19 (16.15) 26.67 (24.93) 4.80 (4.68) 1.49 (2.24) 2.02 (2.80) 1.28 (2.07)
12.80 (10.05) 25.79 (20.02) 3.76 (1.96) 0.84 (0.81) 1.30 (1.17) 0.65 (0.69)
C3 27.71 (29.55) 53.28 (48.45) 6.75 (6.07) 1.08 (1.18)* 1.85 (1.87) 0.77 (0.98)*
25.33 (20.31) 46.20 (35.55) 5.34 (3.20) 0.66 (0.45) 1.29 (0.84) 0.41 (0.33)
Cz 33.63 (31.07) 64.00 (59.68) 6.66 (6.00) 0.94 (1.07)* 1.75 (1.95) 0.62 (0.86)*
29.69 (22.25) 53.44 (40.54) 5.37 (3.59) 0.57 (0.41) 1.20 (0.92) 0.32 (0.25)
C4 28.74 (28.07) 57.95 (52.20) 6.95 (5.94) 1.03 (1.11) 1.85 (1.84) 0.71 (0.87)
27.91 (24.38) 51.69 (40.37) 5.71 (3.15) 0.74 (0.66) 1.30 (0.85) 0.52 (0.77)
T4 15.19 (14.44) 28.78 (24.44) 5.32 (5.30) 1.66 (2.84)* 2.26 (3.24) 1.42 (2.70)*
16.80 (16.04) 29.65 (25.92) 4.11 (2.42) 0.79 (0.72) 1.29 (1.08) 0.59 (0.60)
T5 18.12 (25.17) 57.31 (82.22) 6.38 (11.20) 1.06 (1.65) 1.60 (2.17) 0.85 (1.50)
15.22 (15.74) 36.83 (33.93) 4.13 (2.60) 0.60 (0.64) 1.02 (0.95) 0.43 (0.53)
P3 28.48 (43.05) 69.57 (68.77) 7.95 (8.77) 0.85 (0.83)* 1.57 (1.45) 0.57 (0.62)*
26.28 (26.99) 63.99 (52.76) 6.13 (3.80) 0.54 (0.38) 1.09 (0.68) 0.32 (0.28)
Pz 34.05 (46.94) 80.60 (77.37) 7.94 (8.20) 0.86 (0.79)* 1.60 (1.39) 0.57 (0.60)*
30.61 (26.13) 70.01 (55.88) 6.25 (4.14) 0.55 (0.41) 1.14 (0.78) 0.31 (0.27)
P4 28.03 (35.61) 78.02 (79.29) 8.41 (10.35) 0.86 (0.78)* 1.59 (1.32)* 0.57 (0.60)*
26.20 (24.85) 68.60 (54.93) 6.33 (3.94) 0.50 (0.33) 1.03 (0.60) 0.28 (0.23)
T6 20.40 (24.43) 88.57 (102.61) 8.08 (13.92) 1.17 (2.18) 1.87 (3.09) 0.89 (1.85)
20.38 (22.51) 81.47 (78.64) 6.23 (4.30) 0.62 (0.44) 1.14 (0.71) 0.41 (0.35)
O1 27.77 (34.60) 141.42 (193.68) 12.16 (25.25) 1.26 (1.77)* 2.08 (2.62)* 0.92 (1.49)*
25.00 (24.41) 97.91 (96.68) 7.41 (4.57) 0.60 (0.43) 1.14 (0.63) 0.39 (0.38)
Oz 26.95 (27.79) 159.87 (203.96) 12.51 (24.27) 1.10 (1.29)* 1.90 (1.87)* 0.77 (1.15)*
26.98 (32.25) 124.16 (103.23) 8.68 (7.13) 0.62 (0.47) 1.19 (0.72) 0.39 (0.39)
O2 34.21 (39.13) 126.89 (137.19) 13.81 (20.07) 2.13 (3.45) 3.34 (4.18) 1.65 (3.59)
33.42 (26.24) 101.88 (81.39) 12.03 (9.90) 2.22 (2.88) 3.61 (4.53) 1.66 (2.33)
The mean power (×100) was expressed as “mean (STD)”
The statistical challenge between 5HTTVNTR 10-repeat carriers and non-carriers with P < 0.01 is marked in bold (two-sided)
The threshold of P value after Bonferroni correction is 0.0028; *P < 0.0028
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Page 5 of 10We performed non-parametric analyses to examine
the genetic effect on the global trend. Since the inde-
pendent samples t-test demonstrated significance at
gamma frequency bands for 5-HTTVNTR,o n l yt h e
regional power at frequencies theta, alpha, and beta
were included in the analysis of 5-HTTVNTR.I nc o n -
trast, all electrode-frequency pairs were incorporated in
the analysis of 5-HTTLPR.W eo b s e r v e dt h a t8 2o f1 0 8
(18 electrodes × 6 frequency bands) and 51 of 54 elec-
trode-frequency pairs for 5-HTTLPR and 5-HTTVNTR
showed the same signs after between-group subtraction.
Our non-parametric analyses confirmed a global trend
across the brain: S-allele homozygotes of 5-HTTLPR and
10-repeat allele carriers of 5-HTTVNTR possess lower
regional power, with respective P values 3.071*10
-8 and
1.459*10
-12. Our two-way ANOVA analyses showed no
signification interaction (P < 0.01). In addition, since
only 9 subjects carried the allelic combination of S-allele
of 5-HTTLPR and 10-repeat of 5-HTTNVTR, we did not
conduct further statistical comparisons based on haplo-
types, which could be skewed by the imbalanced sample
distribution.
Our power analyses showed that for 5-HTTLPR,w e
needed 511, 665, 766 and 857 subjects to have 2.5, 5.0,
7.5 and 10.0 percent electrode-frequency pairs to
achieve type 1 error 0.01 and power 0.80, respectively;
whereas for 5-HTTVNTR counterparts, 197, 219, 242
and 261 subjects were required (perspective I). Given
the channel statistics and type 1 error 0.01, the highest
power was 0.66 based on the categorization according
to 5-HTTLPR genotypes, while 33 electrode-frequency
pairs possessed power value greater than 0.80 based on
the categorization according to 5-HTTVNTR genotypes
(perspective II). The power analyses were concordant
with our observation in the 2-sample t-tests, and
endorsed the application of non-parametric analysis,
such as demonstrated in this study, to unveil the data
structure difficult to be quantified by statistical methods
derived from normal distributions.
Discussion
The serotonin transporter (5-HTT) regulates 5-HT
synaptic neurotransmission, which in turn exerts diverse
influences on an organism from embryogenesis through
adulthood [56-62]. A wide variety of psychiatric condi-
tions are associated with the functional polymorphisms
of the 5-HTT gene, such as anxiety, depression, psycho-
sis, alcoholism, obsessive-compulsive disorder, and sui-
cidality [2-12,63]. This study investigated 2 common
functional polymorphisms of 5-HTT, namely, 5-
HTTLPR and 5-HTTVNTR, in order to understand their
genetic contribution to resting brain dynamics. Less effi-
cient transcription and consequently low 5-HTT avail-
ability were associated with the S-allele (S) of 5-
HTTLPR and with the 10-repeat allele of 5-HTTVNTR
when compared to their polymorphic counterparts of
the L-allele (L) and 12-repeat allele. We discovered a
consistent global trend for 5-HTTLPR and 5-HTTVNTR:
t h ea l l e l ew i t hl o wt r a n s c r i ption efficiency was asso-
ciated with low spectral power. For 5-HTTVNTR,t h e
statistical comparison reached significance at gamma
frequencies for “10-repeat allele vs. non-carriers” across
the brain.
5-HTT polymorphism affects synaptic serotonin avail-
ability and modulates event-related potentials. For
example, carriers of more active gene variants are
reported to have increased brain potential in mismatch
negativity and decreased potential in P300 [42,64]. The
extant literature regarding serotonin level, EEG neuro-
matrix, and behavioral phenotypes, nevertheless, seems
to not converge well, with some reports remaining hard
to reconcile. Individuals homozygous for the L-allele of
Figure 1 The topography of t-statistics of mean power differences at gamma frequencies, from the comparison of the group “12-
repeat allele homozygotes” minus the group “10-repeat allele carriers” for 5-HTTVNTR. Left: gamma, middle: gamma1, right: gamma2.
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Page 6 of 105-HTTLPR exhibit a stronger intensity dependence on
auditory-evoked potentials [65], implying a low seroto-
nin level in the brain which agrees well with the innately
high transporter activity [16,66,67]. Studies on serotonin
metabolites in the cerebrospinal fluid have shown that
people with low serotonin level have a substantially high
risk for suicide [68]. However, genetic association stu-
dies have revealed that it is the carriers with the S-allele,
not those with the L-allele, of 5-HTTLPR who possess a
higher suicide risk [69]. Various maneuvers, i.e., apply-
ing a transporter inhibitor or tryptophan depletion, have
been applied to adjust the serotonin level in the central
nervous system but the consequent alterations in EEG
dynamics have been divergent, with both inconsistent
and negative results [27,28,30-32,36]. Thus far, only 1
study has addressed the impact of 5-HTTLPR poly-
morphism on quantitative EEG (qEEG); that study
focused on frontal electrical asymmetry [40]. The reason
that our observed global trend in spectral power change
was not observed in previous research may originate
from fundamental differences in the approach and
design. Several accounts are discussed below.
Lesch et al. showed that carriers of the S-allele of 5-
HTTLPR have higher anxiety-related traits than homo-
zygotes of the L-allele in healthy subjects [12]. Is it pos-
sible that our finding of reduced spectral power in
individuals with the S-allele was mediated by a different
anxiety trait? Knyazev et al. analyzed the participants of
a different anxiety disposition and observed increased
spectral power of all EEG bands in subjects with high-
anxiety traits when they faced an uncertainty condition
[70]. It was unfortunate that Knyazev et al.’sr e s u l t s
were inconsistent with our findings. Is it possible that
our participants of S-allele homozygotes for 5-HTTLPR
or 10-repeat allele carriers for 5-HTTVNTR were in a
higher anxiety state during the EEG recording? The
qEEG studies investigating anxiety state showed
enhanced power of high frequency components [71],
which was replicated in the condition of induced worry
for patients with generalized anxiety disorders [72].
Again, the directionality was contrary to our observa-
tion. Different arousal level is another possibility; how-
ever, heightened arousal was noticed to reduce alpha
power and to increase gamma power [73,74]. We, there-
fore, regard our finding as novel and propose a simple
and unified mechanism to account for our results:
genetic polymorphism contributing to lower 5-HTT
activity is associated with less synchronization of regio-
nal neural organization and consequently with smaller
spectral power, regardless of frequency bands. This
interpretation is simply a straightforward inference from
the observed results.
It is acknowledged that ascending serotonergic projec-
tions from the raphe nuclei to wide brain areas
influence cortical functioning. Most literature is focused
on the concentration of 5-HT, bioavailability of various
5-HT receptors, 5-HT degradation, and the complicated
interplay between intracellular cascades and the accom-
panying up-/down-regulation. It is often ignored that
serotonin is a neurotrophic factor affecting neural archi-
tecture and also a morphogen commencing its influence
during early embryogenesis. 5-HT induces neurogenesis
and neuronal differentiation, affects neuronal migration,
and inhibits the mobility of the growth cone [56-59].
Structural imaging studies have highlighted that the 5-
HTTLPR S-allele is associated with reduced volume at
the hippocampus, caudate nucleus, and prefrontal cor-
tex, and deceased white matter integrity over the fronto-
limbic pathway [75-77]. In adulthood, the serotonergic
system plays a neurotrophic role in the dentate gyrus,
which might be relevant to depression recovery [60-62].
From embryo to adult, serotonergic neurotransmission
exerts diverse influences on the neural architecture and
associated brain function. We speculated that the 5-
HTTLPR S-allele and 5-HTTVNTR 10-repeat allele con-
tributed to less synchronized neural circuits at the local
cortical region. The detrimental effects on neural archi-
tecture at both the local and inter-regional levels might
explain why the S-allele of 5-HTTLPR m a n i f e s t sa sa
general vulnerable factor in so many psychiatric condi-
tions [2-12,63]. 5-HTT polymorphism is reported to
deviate electrocortical activity relevant to attention and
automatic perceptual detection [41,42]. Since gamma
activity has been suggested as correlates of attention
and sensory binding [78-81], the significant differences
in gamma frequency bands for 5-HTTVNTR polymorph-
ism warrant further study to replicate and extend.
Although both 5-HTTLPR and 5-HTTVNTR are func-
tional polymorphisms of the serotonin transporter, stu-
dies that incorporated both genotypes did not always
unveil a consistent association with human phenotypes.
For example, preferential transmission of 5-HTTLPR but
not 5-HTTVNTR genotypes was reported for autism
[24,25]. A tendency toward an increase in the 5-
HTTLPR allele L and VNTR allele 10-repeat, not 12-
repeat, was observed in suicide victims [26]. The degree
of harm avoidance was differentiated by 5-HTTLPR gen-
otypes but not by 5-HTTVNTR [23]. Our result pro-
vided empirical evidence that the impact of 5-HTTLPR
and 5-HTTVNTR was quite consistent at the neural
level (endo-phenotype). We suggest that future studies
recruit both genotypes as an internal validation process,
particularly when the statistics are in the weak to mod-
erate range. We also suggest that studies involving an
activation task attempt the strategy of subtracting base-
line qEEG indices, which might boost the sensitivity of
between-genotype comparisons. Since sex and age have
been observed to effect many EEG indices and, gender
Lee et al. BMC Neuroscience 2011, 12:33
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Page 7 of 10difference has been noticed to moderate the association
between the 5-HTT polymorphism and various pheno-
types [49-51,82-88], whether our findings can be gener-
alized to the male population and whether there exits
chronological interaction warrant further studies to clar-
ify. Although the low frequency of 5-HTTVNTR 10-
repeat allele in our sample (Han Chinese population)
has been observed in other independent research groups
[89,90], we acknowledged that false positive findings
could occur due to skewed allele distribution. Replica-
tion of our results in a larger sample size or in other
races with more balanced 5-HTTVNTR 10-repeat distri-
bution is encouraged.
Conclusion
The serotonin transporter plays a key role in regulating
the synaptic serotonin level. The serotonergic system
also exerts a broad influence on the stage of neurodeve-
lopment. This is the first study using EEG to investigate
the effect of 5-HTTLPR and 5-HTTVNTR polymorphism
on local brain dynamics in the resting state. Our ana-
lyses revealed a global trend of reduced regional power,
regardless of spectral bands, for carriers of the 5-
HTTVNTR 10-repeat allele and those with the 5-
HTTLPR S-allele homozygotes. We speculated that the
5-HTTLPR S-allele and 5-HTTVNTR 10-repeat allele
contributed to less synchronized neural circuits at the
local cortical region. This proposition was endorsed by
previous structural imaging studies that revealed detri-
mental effects associated with the 5-HTTLPR S-allele on
the neural architecture. The implications of our finding
might be relevant to understanding the neural mechan-
ism underlying 5-HTT genetic vulnerability across a
broad range of psychiatric disorders.
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